IM
Inthera develops novel small molecule therapeutics targeting G-protein coupled receptors (GPCRs) for the treatment of serious diseases. The company focuses on creating orally bioavailable drugs designed to modulate specific receptor pathways implicated in various pathologies. Their pipeline aims to deliver targeted treatments with improved efficacy and patient convenience.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Inthera develops novel small molecule therapeutics targeting G-protein coupled receptors (GPCRs) for the treatment of serious diseases. The company focuses on creating orally bioavailable drugs designed to modulate specific receptor pathways implicated in various pathologies. Their pipeline aims to deliver targeted treatments with improved efficacy and patient convenience.